Immunocore Plc(NASDAQ) IMCR

Immunocore Holdings plc helps people with rare cancers and serious diseases fight back. Its treatments use the body’s own immune system to find and kill sick cells. These medicines provide new options for patients with limited choices.

Fighting Disease with T Cells

• KIMMTRAK: A treatment for a rare eye cancer; currently sold in over 30 countries.
• ImmTAX Platform: Proprietary technology used to design medicines that help immune cells find and attack targets inside the body.
• Cancer Pipeline: Several drugs in testing for melanoma, lung cancer, and other solid tumors.
• Infectious Diseases: Early-stage programs aimed at treating chronic conditions like hepatitis B and HIV.
• Autoimmune Care: Research into new ways to treat diseases where the immune system attacks the body.

Expanding the Treatment Map

• Entered a clinical trial collaboration with Bristol-Myers Squibb in Feb. 2024 to study brenetafusp in combination trials.
• Reached the commercial stage following the initial 2022 FDA approval of its lead product, KIMMTRAK.
• Completed a private offering of $402.5 million in senior notes in Feb. 2024 to fund operations.
• Advanced the TEBE-AM Phase 3 clinical trial for cutaneous melanoma with topline data expected as early as late 2026.
• Expanded autoimmune research with clinical sites open for a Phase 1 trial in type 1 diabetes patients.

A Unique Biological Edge

The company has built a global commercial network to deliver its therapies across the United States and Europe. Its unique technology allows it to target solid tumors that are often difficult for other treatments to reach.

By the Numbers

• Total net revenue reached $222.6 million for the six-month period ended June 30, 2026, up 16.0% year over year.
• U.S. sales grew 18.0% to $142.4 million for the six-month period ended June 30, 2026.
• Net income was $12.2 million for the six-month period ended June 30, 2026, compared to a net loss of $5.3 million in the prior year.
• Research and development expenses rose to $135.1 million during the six-month period ended June 30, 2026.
• The company held $484.9 million in cash and $395.3 million in marketable securities as of June 30, 2026.

Evolution of the Business

Immunocore has transitioned from a research lab into a commercial business with a growing global product line. Its expansion into new medical areas shows a focus on using its core technology for various health needs.